OXIS International

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species.The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
OXIS has acquired a 51% interest in and has the option to purchase the remaining 49% of BioCheck, biocheckinc.com. BioCheck, Inc. is a leading provider of high quality enzyme immunoassay research services and products including immunoassay kits for cardiac and tumor markers, infectious diseases, thyroid function, steroids, and fertility hormones. The company operates a 15,000 square-foot, U.S. Food and Drug Administration (FDA) certified cGMP, and ISO device-manufacturing facility near San Francisco, California. BioCheck has advanced developmental programs on two promising cancer biomarkers, related to the Id-gene, and the HMGA2 gene. Id proteins play a significant role in the process of tumor related angiogenesis and other functions related to blood vessel formation. The HMGA2 gene has been implicated in aggressive forms of breast cancer.

Contact Details: 323 Vintage Park Drive Suite B Foster City California 94404 United States of America Tel: 800.547.3686 or 650.212.2568 Fax: 650.212.2569 Email: ussales@oxis.com WWW: www.oxis.com/

Loading...

BioNews Results for OXIS International:
Ergoplex, an anti-inflammatory product, receives good response in direct mail test	News-Medical.Net:  Oct 29 2009 9:31AM Matching: oxis international
OXIS International, Inc. Announces It Has Retained the Law Firm Quinn Emanuel Urquhart Oliver & Hedges, LLP	Genetic Engineering News:  Oct 21 2009 8:18AM Matching: oxis international
OXIS International retains Quinn Emanuel Urquhart Oliver & Hedges to enforce all patents related to L-Ergothio	News-Medical.Net:  Oct 21 2009 8:09AM Matching: oxis international
www.StockMarketingInc.com: Wednesday Watchlist!! PLMO, UNDT, JUNP, OPGX, OXIS	Individual.com:  Oct 21 2009 9:46PM Matching: oxis international

OXIS International Patents:
US Patent No.	Title
6407083	Uses of novel organoselenium compounds with pro-oxidant activity
5543298	Method for assaying the sod activity by using a self-oxidizable compound necessary for its implementation, self-oxidizable compounds and preparation thereof
5817520	Spectrophotometric methods for assaying total mercaptans, reduced glutathione (GSH) and mercaptans other than GSH in an aqueous medium reagents and kits for implementing same
5952187	Topiramate immunoassay
5973009	Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use
→View more OXIS International patents.

OXIS International (OXIS.OB) Financial information Links from Barchart
OXIS.OB Quote from from Barchart.com
OXIS.OB Chart from from Barchart.com
OXIS.OB Profile from from Barchart.com
OXIS.OB Opinion from from Barchart.com
→View more OXIS International finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 389 times since April 2007, the link to the organisation's website has been followed 51 times

Recent Search Terms used to find this page: oxis financial informations | oxis international patents | .

Search for more companies in Foster City

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for OXIS International